460 related articles for article (PubMed ID: 16192580)
1. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
van Meerbeeck JP; Gaafar R; Manegold C; Van Klaveren RJ; Van Marck EA; Vincent M; Legrand C; Bottomley A; Debruyne C; Giaccone G; ;
J Clin Oncol; 2005 Oct; 23(28):6881-9. PubMed ID: 16192580
[TBL] [Abstract][Full Text] [Related]
2. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
Bottomley A; Gaafar R; Manegold C; Burgers S; Coens C; Legrand C; Vincent M; Giaccone G; Van Meerbeeck J; ;
J Clin Oncol; 2006 Mar; 24(9):1435-42. PubMed ID: 16446322
[TBL] [Abstract][Full Text] [Related]
3. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
Bottomley A; Coens C; Efficace F; Gaafar R; Manegold C; Burgers S; Vincent M; Legrand C; van Meerbeeck JP;
J Clin Oncol; 2007 Dec; 25(36):5770-6. PubMed ID: 18089874
[TBL] [Abstract][Full Text] [Related]
4. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
5. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
Berghmans T; Lafitte JJ; Paesmans M; Stach B; Berchier MC; Wackenier P; Lecomte J; Collon T; Mommen P; Sculier JP;
Lung Cancer; 2005 Oct; 50(1):75-82. PubMed ID: 16005104
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
7. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
Porta C; Zimatore M; Bonomi L; Imarisio I; Paglino C; Sartore-Bianchi A; Mutti L
Lung Cancer; 2005 Jun; 48(3):429-34. PubMed ID: 15893013
[TBL] [Abstract][Full Text] [Related]
8. Raltitrexed in mesothelioma.
Surmont VF; van Meerbeeck JP
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1481-90. PubMed ID: 21999120
[TBL] [Abstract][Full Text] [Related]
9. Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
Woods B; Paracha N; Scott DA; Thatcher N
Lung Cancer; 2012 Feb; 75(2):261-7. PubMed ID: 21937141
[TBL] [Abstract][Full Text] [Related]
10. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
[TBL] [Abstract][Full Text] [Related]
12. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
13. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Kasseyet S; Astoul P; Boutin C
Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A
J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838
[TBL] [Abstract][Full Text] [Related]
16. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
Jassem J; Ramlau R; Santoro A; Schuette W; Chemaissani A; Hong S; Blatter J; Adachi S; Hanauske A; Manegold C
J Clin Oncol; 2008 Apr; 26(10):1698-704. PubMed ID: 18375898
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
19. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
